|
|
|
|
Document Preview Broadened Portfolio of Breakthrough Medicines Will Drive Merck's Growth |
||||
|
|
||||
|
Click "Add to Cart" button to purchase document. |
||||
|
|
||||
|
Title: |
Broadened Portfolio of Breakthrough Medicines Will Drive Merck's Growth |
|||
|
Entities: |
Medco Health Solutions Inc.; Merck & Co., Inc.; Schering-Plough Corp. |
|||
|
Date: |
2002 |
|||
|
Size: |
Preview shows 3KB of 24KB total |
|||
|
Price: |
$42 |
|||
|
ID: |
#216984 |
|||
|
|
||||
|
||||
|
|
||||
|
Start of Preview |
||||
Press Contact: Janet Skidmore Investor Contact: Mark Stejbach
(908) 423-3046 (908) 423-5185
Chris Loder
(908) 423-3786
BROADENED PORTFOLIO OF BREAKTHROUGH MEDICINES
WILL DRIVE MERCK'S GROWTH
- LARGE IN-LINE FRANCHISES RANK NO. 1 OR NO. 2 IN WORLDWIDE SALES IN THEIR
CLASS; OUTCOMES STUDIES CONTINUE TO DEMONSTRATE CLINICAL BENEFITS
- COMPANY PLANS TO EXPAND ITS EXISTING FRANCHISES AND ENTER NEW THERAPEUTIC
CATEGORIES WITH NOVEL COMPOUNDS
- NEW CYCLE OF MEDICINES AND VACCINES EXPECTED TO BE FILED OR LAUNCHED BY
2006
WHITEHOUSE STATION, N.J., Dec. 10, 2002 - Merck & Co., Inc. expects to
deliver double-digit growth in its core pharmaceutical business in 2003 by
continuing to demonstrate the clinical benefits of its in-line franchises and
broadening its portfolio of breakthrough medicines, Merck Chairman, President
and CEO Raymond V. Gilmartin told more than 300 securities analysts today at
the company's Annual Business Briefing.
"Merck's strategy of discovering drugs that provide significant clinical
benefits and bringing them to market in an efficient, responsible and ethical
way provides the maximum benefits for patients and creates the greatest value
for shareholders. In today's environment, the successful companies will be those
who have the best science and conduct themselves ethically and with integrity,"
Mr. Gilmartin told the analysts.
"Our large in-line franchises - ZOCOR, VIOXX, FOSAMAX, COZAAR/HYZAAR and
SINGULAIR - are successful because we have demonstrated their clinical benefits
to physicians, patients and payors," Mr. Gilmartin added. "Together, these
products will drive our growth in 2003. Moving forward, we plan to broaden our
portfolio of medicines by expanding our current franchises and moving into new
therapeutic categories."
Merck expanded its cholesterol-modifying franchise in October with the
approval of ZETIA, a cholesterol absorption inhibitor from Merck/Schering-Plough
Pharmaceuticals, and the partnership anticipates filing a New Drug Application
(NDA) with the U.S. Food and Drug Administration (FDA) for a ZETIA/ZOCOR
combination tablet in late 2003. Merck also plans to expand its respiratory
franchise early next year with a seasonal allergic rhinitis indication for
|
End of Preview |
Home Intelligence Services Subscriptions News About Us